Immune activation during pregnancy in rats leads to a postpubertal emergence of disrupted latent inhibition, dopaminergic hyperfunction, and altered limbic morphology in the offspring: A novel neurodevelopmental model of schizophrenia

被引:392
作者
Zuckerman, L
Rehavi, M
Nachman, R
Weiner, I
机构
[1] Tel Aviv Univ, Dept Psychol, Lab Behav Neurosci, IL-69978 Tel Aviv, Israel
[2] Tel Aviv Univ, Sackler Fac Med, Dept Physiol & Pharmacol, IL-69978 Tel Aviv, Israel
关键词
prenatal immune activation; poly I : C; latent inhibition; dopamine; limbic system; schizophrenia; neurodevelopment; BRAIN-DEVELOPMENT; ANIMAL-MODEL; METHYLAZOXYMETHANOL ACETATE; DEPENDENT DIFFERENCES; ANTIPSYCHOTIC-DRUGS; INFLUENZA EPIDEMICS; PREPULSE INHIBITION; PRENATAL EXPOSURE; NUCLEUS-ACCUMBENS; ENTORHINAL CORTEX;
D O I
10.1038/sj.npp.1300248
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Prenatal exposure to infection is associated with increased liability to schizophrenia, and it is believed that such an association is mediated by the maternal immune response, in particular, the proinflammatory cytokines released by the maternal immune system, which may disrupt fetal brain development. Impaired capacity to ignore irrelevant stimuli is one of the central deficits in schizophrenia, and is manifested, among others, in loss of latent inhibition (LI), a phenomenon whereby repeated inconsequential pre-exposure to a stimulus impairs its subsequent capacity to signal significant consequences. We tested the effects of prenatal immune activation induced by peripheral administration of the synthetic cytokine releaser polyriboinosinic - polyribocytidilic acid ( poly I : C) to pregnant dams, on LI in juvenile and adult offspring. Consistent with the characteristic maturational delay of schizophrenia, prenatal immune activation did not affect LI in the juvenile offspring, but led to LI disruption in adulthood. Both haloperidol (0.1 mg/kg) and clozapine ( 5 mg/kg) reinstated LI in the adult offspring. In addition, prenatal immune activation led to a postpubertal emergence of increased sensitivity to the locomotor-stimulating effects of amphetamine and increased in vitro striatal dopamine release, as well as to morphological alterations in the hippocampus and the entorhinal cortex in the adult offspring, consistent with the well-documented mesolimbic dopaminergic and temporolimbic pathology in schizophrenia. These results suggest that prenatal poly I : C administration may provide a neurodevelopmental model of schizophrenia that reproduces a putative inducing factor; mimics the temporal course as well as some central abnormalities of the disorder; and predicts responsiveness to antipsychotic drugs.
引用
收藏
页码:1778 / 1789
页数:12
相关论文
共 103 条
[1]  
Abi-Dargham A, 1998, AM J PSYCHIAT, V155, P761
[2]   EPIDEMIOLOGIC EVIDENCE THAT MATERNAL INFLUENZA CONTRIBUTES TO THE ETIOLOGY OF SCHIZOPHRENIA - AN ANALYSIS OF SCOTTISH, ENGLISH, AND DANISH DATA [J].
ADAMS, W ;
KENDELL, RE ;
HARE, EH ;
MUNKJORGENSEN, P .
BRITISH JOURNAL OF PSYCHIATRY, 1993, 163 :522-534
[3]   THE DISORDER OF CONSCIOUSNESS IN SCHIZOPHRENIA [J].
ANSCOMBE, R .
SCHIZOPHRENIA BULLETIN, 1987, 13 (02) :241-260
[4]   DIFFERENTIAL-EFFECTS OF INTERLEUKIN-1-BETA AND INTERLEUKIN-2 ON GLIA AND HIPPOCAMPAL-NEURONS IN CULTURE [J].
ARAUJO, DM ;
COTMAN, CW .
INTERNATIONAL JOURNAL OF DEVELOPMENTAL NEUROSCIENCE, 1995, 13 (3-4) :201-212
[5]   Neurodevelopmental abnormalities in schizophrenia: Insights from neuropathology [J].
Arnold, SE .
DEVELOPMENT AND PSYCHOPATHOLOGY, 1999, 11 (03) :439-456
[6]  
ARNOLD SE, 1991, ARCH GEN PSYCHIAT, V48, P625
[7]   Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence [J].
Arnt, J ;
Skarsfeldt, T .
NEUROPSYCHOPHARMACOLOGY, 1998, 18 (02) :63-101
[8]   LATENT INHIBITION AND PSYCHOTIC PRONENESS IN NORMAL SUBJECTS [J].
BARUCH, I ;
HEMSLEY, DR ;
GRAY, JA .
PERSONALITY AND INDIVIDUAL DIFFERENCES, 1988, 9 (04) :777-783
[9]   DIFFERENTIAL PERFORMANCE OF ACUTE AND CHRONIC-SCHIZOPHRENICS IN A LATENT INHIBITION TASK [J].
BARUCH, I ;
HEMSLEY, DR ;
GRAY, JA .
JOURNAL OF NERVOUS AND MENTAL DISEASE, 1988, 176 (10) :598-606
[10]  
Bayer S.A., 1991, NEOCORTICAL DEV